JP2020536055A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536055A5 JP2020536055A5 JP2020517334A JP2020517334A JP2020536055A5 JP 2020536055 A5 JP2020536055 A5 JP 2020536055A5 JP 2020517334 A JP2020517334 A JP 2020517334A JP 2020517334 A JP2020517334 A JP 2020517334A JP 2020536055 A5 JP2020536055 A5 JP 2020536055A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- radiation
- administered
- kit
- chemotherapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 33
- 239000003795 chemical substances by application Substances 0.000 claims 24
- 238000002512 chemotherapy Methods 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 22
- 230000005855 radiation Effects 0.000 claims 19
- 229940072107 ascorbate Drugs 0.000 claims 17
- 235000010323 ascorbic acid Nutrition 0.000 claims 17
- 239000011668 ascorbic acid Substances 0.000 claims 17
- 238000001959 radiotherapy Methods 0.000 claims 16
- 206010073306 Exposure to radiation Diseases 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 230000004614 tumor growth Effects 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 2
- 150000001450 anions Chemical group 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 claims 1
- 239000012829 chemotherapy agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 208000037816 tissue injury Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762565436P | 2017-09-29 | 2017-09-29 | |
| US62/565,436 | 2017-09-29 | ||
| PCT/US2018/052826 WO2019067523A1 (en) | 2017-09-29 | 2018-09-26 | FLUOROSUBSTITUTED PORPHYRIN COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF PREPARATION AND USE THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020536055A JP2020536055A (ja) | 2020-12-10 |
| JP2020536055A5 true JP2020536055A5 (enExample) | 2021-11-11 |
| JP7336805B2 JP7336805B2 (ja) | 2023-09-01 |
Family
ID=65903171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517334A Active JP7336805B2 (ja) | 2017-09-29 | 2018-09-26 | フルオロ置換ポルフィリン化合物、該化合物を含む医薬組成物、並びに該化合物を調製及び使用する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11344574B2 (enExample) |
| EP (1) | EP3687551A4 (enExample) |
| JP (1) | JP7336805B2 (enExample) |
| KR (1) | KR102699638B1 (enExample) |
| CN (1) | CN111417400B (enExample) |
| CA (1) | CA3076008A1 (enExample) |
| MX (1) | MX2020002958A (enExample) |
| WO (1) | WO2019067523A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX394244B (es) | 2017-04-04 | 2025-03-24 | Biomimetix Jv Llc | Metodos, composiciones, y kits para tratar y/o prevenir un efecto secundario asociado con radiacion y/o exposicion a quimioterapia |
| EP3687551A4 (en) | 2017-09-29 | 2021-06-23 | Duke University | FLUORUSUBSTITUTED PORPHYRINE COMPOUNDS, THESE PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR MANUFACTURE AND USE |
| CN115192705B (zh) * | 2021-04-13 | 2023-10-13 | 中国科学院化学研究所 | 一种两性离子共价有机聚合物/二氧化钛纳米复合材料及其制备方法和应用 |
| CN116333037A (zh) * | 2021-12-17 | 2023-06-27 | 化学与精细化工广东省实验室 | 含巯基肽与氟代卟啉类偶联用作生物探针 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2520735B2 (ja) * | 1988-07-14 | 1996-07-31 | 東洋薄荷工業株式会社 | ポルフィリン誘導体 |
| EP1045851B1 (en) | 1997-11-03 | 2003-04-23 | Duke University | Substituted porphyrins |
| JPH11217385A (ja) * | 1998-01-30 | 1999-08-10 | Nihon Schering Kk | 含フッ素ポルフィリン錯体およびそれを含有する造影剤 |
| US6448239B1 (en) | 1999-06-03 | 2002-09-10 | Trustees Of Princeton University | Peroxynitrite decomposition catalysts and methods of use thereof |
| US20030050297A1 (en) | 2001-01-19 | 2003-03-13 | Crapo James D. | Cancer therapy |
| EP1718201B1 (en) | 2004-02-09 | 2016-09-14 | Duke University | Substituted porphyrins |
| BRPI0509359A (pt) * | 2004-03-29 | 2007-09-04 | Inotek Pharmaceuticals Corp | compostos de porfirina substituìda por piridila e métodos de empregos destes |
| CN101235036A (zh) | 2007-02-02 | 2008-08-06 | 济南赛文医药技术有限公司 | 一类卟啉衍生物及其作为小分子抗氧化剂的应用 |
| GB0819594D0 (en) * | 2008-10-24 | 2008-12-03 | Univ Coimbrra | Process |
| WO2010080881A1 (en) * | 2009-01-07 | 2010-07-15 | Duke University | Substituted porphyrins |
| WO2015034778A1 (en) | 2013-09-03 | 2015-03-12 | Biomimetix J.V., Llc | Methods of treating erectile dysfunction |
| US10080759B2 (en) | 2014-01-22 | 2018-09-25 | Duke University | Methods of treating pruritus |
| US10064871B2 (en) | 2014-01-22 | 2018-09-04 | Biomimetix Jv, Llc | Methods of treating skin disorders |
| EP3558902A4 (en) * | 2016-12-20 | 2020-06-24 | Duke University | METHOD FOR PRODUCING PHARMACEUTICAL COMPOUNDS WITH SUBSTITUTED PORPHYRINE AND COMPOSITIONS |
| WO2018237249A1 (en) | 2017-06-22 | 2018-12-27 | Biomimetix Jv, Llc | Methods, compositions, and kits for treating inflammatory skin conditions |
| EP3687551A4 (en) | 2017-09-29 | 2021-06-23 | Duke University | FLUORUSUBSTITUTED PORPHYRINE COMPOUNDS, THESE PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR MANUFACTURE AND USE |
-
2018
- 2018-09-26 EP EP18861582.7A patent/EP3687551A4/en active Pending
- 2018-09-26 MX MX2020002958A patent/MX2020002958A/es unknown
- 2018-09-26 US US16/645,907 patent/US11344574B2/en active Active
- 2018-09-26 CA CA3076008A patent/CA3076008A1/en active Pending
- 2018-09-26 KR KR1020207010074A patent/KR102699638B1/ko active Active
- 2018-09-26 WO PCT/US2018/052826 patent/WO2019067523A1/en not_active Ceased
- 2018-09-26 JP JP2020517334A patent/JP7336805B2/ja active Active
- 2018-09-26 CN CN201880077161.7A patent/CN111417400B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536055A5 (enExample) | ||
| Lee et al. | Dietary flaxseed prevents radiation-induced oxidative lung damage, inflammation and fibrosis in a mouse model of thoracic radiation injury | |
| Ramírez et al. | New non-bisphosphonate drugs that produce osteonecrosis of the jaws | |
| JP2013501731A5 (enExample) | ||
| JP2019534308A5 (enExample) | ||
| JP2019529581A5 (enExample) | ||
| Liu et al. | Caffeic acid phenethyl ester as an adjuvant therapy for advanced prostate cancer | |
| JP2017516802A5 (enExample) | ||
| JP2016515586A5 (enExample) | ||
| Jackson et al. | BIO 300, a nanosuspension of genistein, mitigates radiation-induced erectile dysfunction and sensitizes human prostate cancer xenografts to radiation therapy | |
| JP2019508476A5 (enExample) | ||
| RU2019121690A (ru) | Дексмедетомидин или медетомидин для применения для лечения сепарационной тревожности у собак | |
| JP2019510807A5 (enExample) | ||
| RU2006123939A (ru) | Лечение остеопороза, связанного с терапией ингибиторами ароматазы | |
| JP2020531495A5 (enExample) | ||
| JP2017527627A (ja) | 喫煙者における非小細胞肺癌の治療のための、カルボプラチンおよびパクリタキセルと併用したベリパリブ | |
| JP2020515630A5 (ja) | 放射線及び／又は化学療法の曝露に関連付けられる副作用を処置及び／又は防止する剤、組成物及びキット | |
| JP2020536903A5 (enExample) | ||
| Gobitti et al. | Treatment of recurrent high-grade gliomas with GliaSite brachytherapy: a prospective mono-institutional Italian experience | |
| US10702534B2 (en) | Compositions and methods relating to the radioprotective effects of apilimod | |
| O’kane et al. | Vismodegib in the treatment of advanced BCC | |
| CN114081880B (zh) | 木香内酯及其衍生物在制备预防和/或治疗肠损伤的药物中的用途 | |
| RU2834842C2 (ru) | Способ лечения рецидивов высокозлокачественных глиом головного мозга | |
| CA3135916A1 (en) | Combined use of a-nor-5a androstane compound drug and anticancer drug | |
| CN111971046A (zh) | 用于防护或减轻辐射损伤以及用于预防或治疗肺纤维化的用途 |